The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) is a huge mover today! The stock decreased 5.49% or $0.54 on November 30, hitting $9.29. About 1.44 million shares traded hands or 41.18% up from the average. Ocular Therapeutix Inc (NASDAQ:OCUL) has declined 21.36% since April 27, 2016 and is downtrending. It has underperformed by 26.59% the S&P500.
The move comes after 9 months negative chart setup for the $223.85M company. It was reported on Nov, 30 by Barchart.com. We have $8.45 PT which if reached, will make NASDAQ:OCUL worth $20.15 million less.
Analysts await Ocular Therapeutix Inc (NASDAQ:OCUL) to report earnings on March, 9. They expect $-0.47 EPS, down 9.30% or $0.04 from last year’s $-0.43 per share. After $-0.39 actual EPS reported by Ocular Therapeutix Inc for the previous quarter, Wall Street now forecasts 20.51% negative EPS growth.
Ocular Therapeutix Inc (NASDAQ:OCUL) Ratings Coverage
Out of 4 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ocular Therapeutix has been the topic of 8 analyst reports since August 5, 2015 according to StockzIntelligence Inc. Nomura initiated Ocular Therapeutix Inc (NASDAQ:OCUL) on Wednesday, August 5 with “Buy” rating. Morgan Stanley initiated the stock with “Equal Weight” rating in Thursday, August 13 report. JMP Securities initiated the shares of OCUL in a report on Thursday, August 11 with “Outperform” rating. Morgan Stanley maintained it with “Overweight” rating and $17 target price in Thursday, April 28 report. The firm earned “Overweight” rating on Thursday, February 18 by Morgan Stanley. The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) earned “Outperform” rating by RBC Capital Markets on Tuesday, November 15. The firm has “Overweight” rating given on Tuesday, June 7 by Morgan Stanley. The company was downgraded on Friday, October 23 by Morgan Stanley.
According to Zacks Investment Research, “Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts.”
Another recent and important Ocular Therapeutix Inc (NASDAQ:OCUL) news was published by Investorplace.com which published an article titled: “Why CSX Corporation (CSX), Ocular Therapeutix Inc (OCUL), and Ulta Salon …” on October 13, 2016.
OCUL Company Profile
Ocular Therapeutix, Inc., incorporated on September 12, 2006, is a biopharmaceutical company. The Firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. The Company’s hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.